Researchers from Insilico Medicine and Eli Lilly published a vision in ACS Central Science outlining a fully autonomous, AI‑driven 'prompt‑to‑drug' pipeline that integrates generative models across target ID, design, synthesis planning, and in silico evaluation. The paper synthesizes advances in generative AI, automated synthesis and predictive assays, and lays out technical and regulatory hurdles for deploying end‑to‑end automation in pharmaceutical R&D. The framework signals increasing alignment between large pharma and AI startups on investment in automation, and will influence how companies prioritize computational platforms and lab automation to compress discovery timelines.